3 registrations that name akkermansia muciniphila as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
All 3 registrations
Not yet recruitingNCT07415473
Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease
Phase 4
Chinese Medical Association
About 400 people
Starts Apr 1, 2026 (estimated)
In plain words A Phase 4 study of akkermansia muciniphila in people 18 to 75, run by Chinese Medical Association. It plans to enroll about 400 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Crohn's Diseases.
Adult patients aged 18 to 75 years.
Documented diagnosis of Crohn's disease established at any time prior to screening by radiological, histological, or endoscopic evidence.
Active Crohn's disease at screening, defined as a Crohn's Disease Activity Index (CDAI) score between 220 and 450 (inclusive).
Adequate cardiac, renal and hepatic function, as assessed by the investigator based on screening laboratory tests, physical examination, and medical history, without findings that would pose an undue risk for study participation.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Infliximab; Akkermansia muciniphila + Infliximab
Registered summary
This study aims to evaluate whether the combination of Akkermansia muciniphila with infliximab can improve intestinal mucosal healing in patients with Crohn's disease compared with infliximab alone.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07295353
Accelerating Recovery After ICU Admission: Post-discharge Supplementation With Pasteurized Akkermansia Muciniphila.
No phase
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
About 50 people
Starts Jan 2026 (estimated)
In plain words A study of akkermansia muciniphila in people 18 and older, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). It plans to enroll about 50 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Sepsis; Post Intensive Care Unit Syndrome; Critical Illness; Microbiome Dysbiosis; Intensive Care Unit Survivors.
Age ≥18 years
Treated in the ICU for at least 2 days and discharged to a regular clinical ward
Diagnosed with sepsis during ICU admission
Received selective digestive decontamination (SDD) or cephalosporin
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Pasteurized Akkermansia muciniphila; Placebo Control
Registered summary
The goal of this clinical trial is to learn if daily oral supplementation with pasteurized Akkermansia muciniphila (PAM), an EFSA-approved food supplement, can support recovery in adults who have recently been treated in the ICU for sepsis. The main questions it aims to answer are: * Is PAM safe to take for 56 days after ICU discharge? * Does PAM increase the abundance of beneficial butyrate-producing bacteria in the gut? Researchers will compare PAM to a placebo (a capsule that looks the same but has no active ingredient) to see if PAM improves gut microbiota and immune recovery. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06992154
Role of Akkermansia Muciniphila in Acne Vulgaris
Early phase 1
Medical University of South Carolina
About 34 people
Starts Mar 2027 (estimated)
In plain words An early phase 1 study of akkermansia muciniphila in people 18 to 45, run by Medical University of South Carolina. It plans to enroll about 34 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45. Conditions: Acne.
Participants aged 18 to 45 years.
Individuals with clinically diagnosed moderate to severe acne vulgaris, determined using standardized scales like the Global Acne Grading
System (GAGS) by Investigators of the study.
Willingness to provide informed consent and adhere to study protocols, including follow-ups and sample collections.
The project explores the use of Pendulum's Glucose Control, which contains a unique combination of probiotics, including Akkermansia muciniphila, Clostridium beijerinckii, Anaerobutyricum hallii, Clostridium butyricum, and Bifidobacterium infantis, to treat acne by improving gut health and reducing inflammation. The full summary is on the listing.
Where, as registered
No sites listed yet.
ClinicalTrials.gov lists 18 open registrations for this search, including ones where akkermansia muciniphila is not a study arm or that are past the 3 we keep. Search them on ClinicalTrials.gov (opens in new tab).